Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
12.46
+0.20 (1.59%)
At close: Nov 5, 2025, 4:00 PM EST
12.60
+0.14 (1.16%)
Pre-market: Nov 6, 2025, 4:02 AM EST
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts that cover Nurix Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $26.29, which forecasts a 111.08% increase in the stock price over the next year. The lowest target is $15 and the highest is $35.
Price Target: $26.29 (+111.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nurix Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 5 | 5 |
| Buy | 8 | 7 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 16 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $26 | Strong Buy | Reiterates | $26 | +108.75% | Nov 4, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +116.78% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $33 → $28 | Strong Buy | Maintains | $33 → $28 | +124.81% | Oct 27, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +68.61% | Oct 23, 2025 |
| BTIG | BTIG | Strong Buy Maintains $35 → $27 | Strong Buy | Maintains | $35 → $27 | +116.78% | Oct 23, 2025 |
Financial Forecast
Revenue This Year
86.45M
from 54.55M
Increased by 58.48%
Revenue Next Year
54.96M
from 86.45M
Decreased by -36.42%
EPS This Year
-3.21
from -2.88
EPS Next Year
-3.50
from -3.21
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 114.2M | 99.8M | ||||
| Avg | 86.4M | 55.0M | ||||
| Low | 69.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 109.4% | 15.4% | ||||
| Avg | 58.5% | -36.4% | ||||
| Low | 26.5% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.09 | -2.24 | ||||
| Avg | -3.21 | -3.50 | ||||
| Low | -3.32 | -4.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.